Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Long-term survivorship challenges in advanced urothelial cancer

Jonathan Rosenberg • 5 Jun 2022
ASCO 2022
Bladder Cancer Genitourinary Cancer Enfortumab vedotin

Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, provides an overview of survivorship challenges faced by patients with bladder cancer, which vary with extent and stage of disease. In metastatic patients, peripheral neuropathy is a long-term toxicity associated with the use of enfortumab vedotin, an antibody-drug conjugate. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Jonathan Rosenberg

0:57
PROs in advanced cisplatin-ineligible UC: first-line EV ± pembrolizumab
Jonathan Rosenberg • 7 Apr 2024
1:05
HRQoL in patients with previously treated advanced urothelial carcinoma from EV-301: EV vs chemo
Jonathan Rosenberg • 7 Apr 2024
2:15
LY4101174, a novel nectin-4-targeting ADC in solid tumors
Jonathan Rosenberg • 7 Apr 2024
0:44
Antibody-drug conjugates for advanced bladder cancer
Jonathan Rosenberg • 11 Sep 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals